ACT Genomics

About ACT Genomics

ACT Genomics positions itself as a specialized cancer solutions provider, leveraging genomic information to advance precision medicine. Founded in 2014 by scientists Hua Chien Chen, Shu Jen Chen, and Joe Hsueh, the company was established with the goal of translating academic genomic research into practical clinical applications for personalized cancer care. Hua Chien Chen, the CEO, brings over two decades of experience in cancer biology, genomics, and drug discovery, including roles at the National Health Research Institute in Taiwan and as a Biology Director at TaiGen Biotechnology. His background in molecular biology and oncology underpins the company's scientific direction.

The company's business model is centered on providing comprehensive genomic profiling assays and molecular information to physicians, biopharmaceutical clients, and directly to patients. It operates in the precision oncology market, serving clients across Asia with offices in Taiwan, Hong Kong, Singapore, and Tokyo. Revenue is generated through its genomic testing services, which assist in treatment planning, monitoring for cancer relapse and drug resistance, and assessing cancer risk. The company also collaborates with pharmaceutical firms to identify drug development targets and stratify patients for clinical trials. A key milestone was the acquisition of a majority stake by Prenetics in December 2022, and subsequently, an acquisition by Delta Electronics was approved in June 2025 to enhance Delta's healthcare portfolio.

ACT Genomics' core offering is its Next-Generation Sequencing (NGS) services. Its flagship product, ACTOnco®, is a comprehensive genomic profiling test for all solid tumors that analyzes 440 cancer-related genes to inform treatment decisions. In a significant achievement, ACTOnco® received clearance from the U.S. Food and Drug Administration (FDA), a first for an Asia-based company for such a test. Beyond ACTOnco®, the company offers a suite of products for cancer risk screening, early detection, and monitoring, such as the ACTMonitor test for colon cancer. These services provide clinicians with evidence-based insights to tailor treatment plans, including targeted therapies and immunotherapies, based on a patient's specific genomic alterations.